Shares of Gilead Sciences Inc. rose 4.21% to $122.81 Friday, on what proved to be an all-around great trading session for the ...

Gilead Sciences (GILD) is drawing attention this week as it presents new clinical results at both the European AIDS ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Gilead Sciences and Arcus Biosciences’ anti-TIGIT antibody domvanalimab has been tied to median overall survival of close to ...

The biopharma will aim to bolster its pipeline, with plans to present updated results for novel long-acting combination ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best stocks to buy according to Jim Simons’ Renaissance Technologies. On ...

GSK’s ViiV Healthcare and its bimonthly pre-exposure prophylaxis (PrEP) medicine Apretude had to make room for another ...

Gilead Sciences Inc. (GILD) reached a notable milestone as its stock hit a 52-week high of $121.84, with InvestingPro data ...

Gilead Sciences settled patent disputes with Lupin, Cipla, and Laurus, delaying U.S. generic entry of HIV drug Biktarvy until ...

The partnership is part of Boys & Girls Clubs of America’s ongoing commitment to prepare America’s youth for life and work. As the U.S. faces a projected shortfall of 1.4 million skilled workers by ...

US pharma major Gilead Sciences (Nasdaq: GILD) used the European AIDS Conference in Paris to showcase progress across its HIV ...

Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab ...